MAP2K7 and Miyoshi myopathy: In addition, a phase 2 ROAR trial (NCT02034110) evaluated the efficacy and safety of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in MM patients harboring the BRAFV600E mutation, showing an ORR of 50%, a median duration of response (DOR) of 11.1 months, a median PFS of 6.3 months, and a median OS of 33.9 months [104].